QUEST informs readers of the latest advances in urologic prostate cancer research, especially detection, prevention, and treatment.
A recent review article on BRCA1- and BRCA2- associated cancer risks and management of male patients updates and brings into focus information that has been covered far more extensively in the media than the risks for breast and ovarian cancer…
At the annual meeting of the Society of Urologic Oncology (SUO) held in the fall of 2023, Dr. Catalona gave an invited lecture to urologic oncologists on the Genetics of Prostate Cancer. This article is a condensation and simplification of…
A study, recently presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium in San Francisco found that high-risk prostate cancer patients benefit from dose-escalation radiotherapy in combination with long-term androgen deprivation therapy (ADT) with no increase in long-term…
The Prostate Cancer Foundation recently released screening recommendations for Black men. A PSA should be the first-line test for prostate cancer screening. Black men with a heightened risk for prostate cancer due to a strong family history or being a…
Results from a recently presented study found that the Stockhom3 blood test for prostate cancer risk stratification reduces unnecessary prostate biopsies and diagnoses of grade 1 prostate cancers. The multi-ethnic study included Black, White, Hispanic, and Asian individuals. The researchers…
Andrew Fox’s lifetime love affair with trains has provided him with a vocation, an avocation, and plenty of adventures. Andrew grew up in northern California and from an early age was fascinated by trains. He got his first job…
A recent study reported differences in the use of novel hormonal therapy (NHT) among Medicare beneficiaries with advanced prostate cancer (PC) based on their race. Researchers studied how NHT was used among men diagnosed with advanced PC between January 1,…
New study results found that Cabozantinib plus Atezolizumab (C+A) can significantly improve prognoses of patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed with prior novel hormonal therapy. This phase 3 study, found that patients in the C+A…
In this phase III trial, researchers compared treatments for patients with recurring prostate cancer. They looked at using hormone therapy alone, hormone therapy with apalutamide, or hormone therapy with abiraterone/prednisone and apalutamide. Patients had previously had surgery and had a…
(de novo is a phrase from Latin describing some biological process that has begun again) During a period with improvements in the treatment of advanced prostate cancer, there was a simultaneous clinically meaningful increase in mean survival for men with…
"*" indicates required fields
